SwePub - sökning: WFRF:(Battelino T)

Numrering	Referens	Omslagsbild	Hitta
1.	Abdo, A. A., et al. (författare) Fermi Observations of High-Energy Gamma-Ray Emission from GRB 080916C 2009 Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 323:5922, s. 1688-1693 Tidskriftsartikel (refereegranskat)abstract Gamma-ray bursts (GRBs) are highly energetic explosions signaling the death of massive stars in distant galaxies. The Gamma-ray Burst Monitor and Large Area Telescope onboard the Fermi Observatory together record GRBs over a broad energy range spanning about 7 decades of gamma-ray energy. In September 2008, Fermi observed the exceptionally luminous GRB 080916C, with the largest apparent energy release yet measured. The high-energy gamma rays are observed to start later and persist longer than the lower energy photons. A simple spectral form fits the entire GRB spectrum, providing strong constraints on emission models. The known distance of the burst enables placing lower limits on the bulk Lorentz factor of the outflow and on the quantum gravity mass.
2.	Abdo, A. A., et al. (författare) FERMI/LARGE AREA TELESCOPE BRIGHT GAMMA-RAY SOURCE LIST 2009 Ingår i: Astrophysical Journal Supplement Series. - : American Astronomical Society. - 0067-0049 .- 1538-4365. ; 183:1, s. 46-66 Tidskriftsartikel (refereegranskat)abstract Following its launch in 2008 June, the Fermi Gamma-ray Space Telescope (Fermi) began a sky survey in August. The Large Area Telescope (LAT) on Fermi in three months produced a deeper and better resolved map of the gamma-ray sky than any previous space mission. We present here initial results for energies above 100 MeV for the 205 most significant (statistical significance greater than similar to 10 sigma) gamma-ray sources in these data. These are the best characterized and best localized point-like (i.e., spatially unresolved) gamma-ray sources in the early mission data.
3.	Aharonian, F., et al. (författare) SIMULTANEOUS OBSERVATIONS OF PKS 2155-304 WITH HESS, FERMI, RXTE, AND ATOM : SPECTRAL ENERGY DISTRIBUTIONS AND VARIABILITY IN A LOW STATE 2009 Ingår i: Astrophysical Journal Letters. - 2041-8205 .- 0004-637X .- 1538-4357. ; 696:2, s. L150-L155 Tidskriftsartikel (refereegranskat)abstract We report on the first simultaneous observations that cover the optical, X-ray, and high-energy gamma-ray bands of the BL Lac object PKS 2155-304. The gamma-ray bands were observed for 11 days, between 2008 August 25 and 2008 September 6 (MJD 54704-54715), jointly with the Fermi Gamma-ray Space Telescope and the HESS atmospheric Cherenkov array, providing the first simultaneous MeV-TeV spectral energy distribution (SED) with the new generation of gamma-ray telescopes. The ATOM telescope and the RXTE and Swift observatories provided optical and X-ray coverage of the low-energy component over the same time period. The object was close to the lowest archival X-ray and very high energy (VHE; > 100 GeV) state, whereas the optical flux was much higher. The light curves show relatively little (similar to 30%) variability overall when compared to past flaring episodes, but we find a clear optical/VHE correlation and evidence for a correlation of the X-rays with the high-energy spectral index. Contrary to previous observations in the flaring state, we do not find any correlation between the X-ray and VHE components. Although synchrotron self-Compton models are often invoked to explain the SEDs of BL Lac objects, the most common versions of these models are at odds with the correlated variability we find in the various bands for PKS 2155-304.
4.	Abdo, A. A., et al. (författare) Measurement of the Cosmic Ray e(+)+e(-) Spectrum from 20 GeV to 1 TeV with the Fermi Large Area Telescope 2009 Ingår i: Physical Review Letters. - 0031-9007 .- 1079-7114. ; 102:Article number: 181101 Tidskriftsartikel (refereegranskat)abstract Designed as a high-sensitivity gamma-ray observatory, the Fermi Large Area Telescope is also an electron detector with a large acceptance exceeding 2 m(2) sr at 300 GeV. Building on the gamma-ray analysis, we have developed an efficient electron detection strategy which provides sufficient background rejection for measurement of the steeply falling electron spectrum up to 1 TeV. Our high precision data show that the electron spectrum falls with energy as E-3.0 and does not exhibit prominent spectral features. Interpretations in terms of a conventional diffusive model as well as a potential local extra component are briefly discussed.
5.	Abdo, A. A., et al. (författare) PULSED GAMMA-RAYS FROM PSR J2021+3651 WITH THE FERMI LARGE AREA TELESCOPE 2009 Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 700:2, s. 1059-1066 Tidskriftsartikel (refereegranskat)abstract We report the detection of pulsed gamma-rays from the young, spin-powered radio pulsar PSR J2021+3651 using data acquired with the Large Area Telescope (LAT) on the Fermi Gamma-ray Space Telescope (formerly GLAST). The light curve consists of two narrow peaks of similar amplitude separated by 0.468 +/- 0.002 in phase. The first peak lags the maximum of the 2 GHz radio pulse by 0.162 +/- 0.004 +/- 0.01 in phase. The integral gamma-ray photon flux above 100 MeV is (56 +/- 3 +/- 11) x 10(-8) cm(-2) s(-1). The photon spectrum is well described by an exponentially cut-off power law of the form dF/dE = kE(-Gamma)e((-E/Ec)), where the energy E is expressed in GeV. The photon index is Gamma = 1.5 +/- 0.1 +/- 0.1 and the exponential cut-off is E-c = 2.4 +/- 0.3 +/- 0.5 GeV. The first uncertainty is statistical and the second is systematic. The integral photon flux of the bridge is approximately 10% of the pulsed emission, and the upper limit on off-pulse gamma-ray emission from a putative pulsar wind nebula is < 10% of the pulsed emission at the 95% confidence level. Radio polarization measurements yield a rotation measure of RM = 524 +/- 4 rad m(-2) but a poorly constrained magnetic geometry. Re-analysis of Chandra X-ray Observatory data enhanced the significance of the weak X-ray pulsations, and the first peak is roughly phase aligned with the first gamma-ray peak. We discuss the emission region and beaming geometry based on the shape and spectrum of the gamma-ray light curve combined with radio and X-ray measurements, and the implications for the pulsar distance. Gamma-ray emission from the polar cap region seems unlikely for this pulsar.
6.	Meech, K. J., et al. (författare) EPOXI: Comet 103P/Hartley 2 Observations from a Worldwide Campaign 2011 Ingår i: Astrophysical Journal Letters. - London : IOP. - 2041-8213 .- 2041-8205. ; 734:L1, s. 1-9 Tidskriftsartikel (refereegranskat)abstract Earth- and space-based observations provide synergistic information for space mission encounters by providing data over longer timescales, at different wavelengths and using techniques that are impossible with an in situ flyby. We report here such observations in support of the EPOXI spacecraft flyby of comet 103P/Hartley 2. The nucleus is small and dark, and exhibited a very rapidly changing rotation period. Prior to the onset of activity, the period was ~16.4?hr. Starting in 2010 August the period changed from 16.6?hr to near 19?hr in December. With respect to dust composition, most volatiles and carbon and nitrogen isotope ratios, the comet is similar to other Jupiter-family comets. What is unusual is the dominance of CO 2 -driven activity near perihelion, which likely persists out to aphelion. Near perihelion the comet nucleus was surrounded by a large halo of water-ice grains that contributed significantly to the total water production.
7.	Abdo, A. A., et al. (författare) EARLY FERMI GAMMA-RAY SPACE TELESCOPE OBSERVATIONS OF THE QUASAR 3C 454.3 2009 Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 699:1, s. 817-823 Tidskriftsartikel (refereegranskat)abstract This is the first report of Fermi Gamma-Ray Space Telescope observations of the quasar 3C 454.3, which has been undergoing pronounced long-term outbursts since 2000. The data from the Large Area Telescope, covering 2008 July 7-October 6, indicate strong, highly variable.-ray emission with an average flux of similar to 3 x 10 (6) photons cm(-2) s(-1), for energies > 100 MeV. The gamma-ray flux is variable, with strong, distinct, symmetrically shaped flares for which the flux increases by a factor of several on a timescale of about 3 days. This variability indicates a compact emission region, and the requirement that the source is optically thin to pair production implies relativistic beaming with Doppler factor delta > 8, consistent with the values inferred from Very Long Baseline Interferometry observations of superluminal expansion (delta similar to 25). The observed gamma-ray spectrum is not consistent with a simple power law, but instead steepens strongly above similar to 2 GeV, and is well described by a broken power law with photon indices of similar to 2.3 and similar to 3.5 below and above the break, respectively. This is the first direct observation of a break in the spectrum of a high-luminosity blazar above 100 MeV, and it is likely direct evidence for an intrinsic break in the energy distribution of the radiating particles. Alternatively, the spectral softening above 2 GeV could be due to gamma-ray absorption via photon-photon pair production on the soft X-ray photon field of the host active galactic nucleus, but such an interpretation would require the dissipation region to be located very close (less than or similar to 100 gravitational radii) to the black hole, which would be inconsistent with the X-ray spectrum of the source.
8.	Abdo, A. A., et al. (författare) FERMI/LARGE AREA TELESCOPE DISCOVERY OF GAMMA-RAY EMISSION FROM A RELATIVISTIC JET IN THE NARROW-LINE QUASAR PMN J0948+0022 2009 Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 699:2, s. 976-984 Tidskriftsartikel (refereegranskat)abstract We report the discovery by the Large Area Telescope (LAT) onboard the Fermi Gamma-Ray Space Telescope of high-energy. gamma-ray emission from the peculiar quasar PMN J0948+0022 (z = 0.5846). The optical spectrum of this object exhibits rather narrow H beta (FWHM(H beta) similar to 1500 km s(-1)), weak forbidden lines, and is therefore classified as a narrow-line type I quasar. This class of objects is thought to have relatively small black hole mass and to accrete at a high Eddington ratio. The radio loudness and variability of the compact radio core indicate the presence of a relativistic jet. Quasi-simultaneous radio/optical/X-ray and gamma-ray observations are presented. Both radio and gamma-ray emissions (observed over five months) are strongly variable. The simultaneous optical and X-ray data from Swift show a blue continuum attributed to the accretion disk and a hard X-ray spectrum attributed to the jet. The resulting broadband spectral energy distribution (SED) and, in particular, the gamma-ray spectrum measured by Fermi are similar to those of more powerful Flat-Spectrum Radio Quasars (FSRQs). A comparison of the radio and gamma-ray characteristics of PMN J0948+0022 with the other blazars detected by LAT shows that this source has a relatively low radio and gamma-ray power with respect to other FSRQs. The physical parameters obtained from modeling the SED also fall at the low power end of the FSRQ parameter region discussed in Celotti & Ghisellini. We suggest that the similarity of the SED of PMN J0948+0022 to that of more massive and more powerful quasars can be understood in a scenario in which the SED properties depend on the Eddington ratio rather than on the absolute power.
9.	Abdo, A. A., et al. (författare) PULSED GAMMA RAYS FROM THE MILLISECOND PULSAR J0030+0451 WITH THE FERMI LARGE AREA TELESCOPE 2009 Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 699:2, s. 1171-1177 Tidskriftsartikel (refereegranskat)abstract We report the discovery of gamma-ray pulsations from the nearby isolated millisecond pulsar (MSP) PSR J0030+0451 with the Large Area Telescope on the Fermi Gamma-ray Space Telescope (formerly GLAST). This discovery makes PSR J0030+0451 the second MSP to be detected in gamma rays after PSR J0218+4232, observed by the EGRET instrument on the Compton Gamma-Ray Observatory. The spin-down power (E) over dot = 3.5 x 10(33) erg s(-1) is an order of magnitude lower than the empirical lower bound of previously known gamma-ray pulsars. The emission profile is characterized by two narrow peaks, 0.07 +/- 0.01 and 0.08 +/- 0.02 wide, respectively, separated by 0.44 +/- 0.02 in phase. The first gamma-ray peak falls 0.15 +/- 0.01 after the main radio peak. The pulse shape is similar to that of the "normal" gamma-ray pulsars. An exponentially cutoff power-law fit of the emission spectrum leads to an integral photon flux above 100 MeV of (6.76 +/- 1.05 +/- 1.35) x 10(-8) cm(-2) s(-1) with cutoff energy (1.7 +/- 0.4 +/- 0.5) GeV. Based on its parallax distance of (300 +/- 90) pc, we obtain a gamma-ray efficiency L-gamma/E similar or equal to 15% for the conversion of spin-down energy rate into gamma-ray radiation, assuming isotropic emission.
10.	Klonoff, D. C., et al. (författare) A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings 2022 Ingår i: Journal of Diabetes Science and Technology. - : SAGE Publications. - 1932-2968. Tidskriftsartikel (refereegranskat)abstract Background: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data. Methods: We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low–glucose and low-glucose hypoglycemia; very high–glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation. Results: The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals. Conclusion: The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.
11.	Prigge, R., et al. (författare) International comparison of glycaemic control in people with type 1 diabetes: an update and extension 2022 Ingår i: Diabetic Medicine. - : Wiley. - 0742-3071 .- 1464-5491. ; 39:5 Tidskriftsartikel (refereegranskat)abstract Aims: To update and extend a previous cross-sectional international comparison of glycaemic control in people with type 1 diabetes. Methods: Data were obtained for 520,392 children and adults with type 1 diabetes from 17 population and five clinic-based data sources in countries or regions between 2016 and 2020. Median HbA1c(IQR) and proportions of individuals with HbA1c < 58mmol/mol (<7.5%), 58–74mmol/mol (7.5–8.9%) and ≥75mmol/mol (≥9.0%) were compared between populations for individuals aged <15, 15–24 and ≥25 years. Logistic regression was used to estimate the odds ratio (OR) of HbA1c < 58mmol/mol (<7.5%) relative to ≥58mmol/mol (≥7.5%), stratified and adjusted for sex, age and data source. Where possible, changes in the proportion of individuals in each HbA1c category compared to previous estimates were calculated. Results: Median HbA1c varied from 55 to 79mmol/mol (7.2 to 9.4%) across data sources and age groups so a pooled estimate was deemed inappropriate. OR (95% CI) for HbA1c< 58mmol/mol (<7.5%) were 0.91 (0.90–0.92) for women compared to men, 1.68 (1.65–1.71) for people aged <15years and 0.81 (0.79–0.82) aged15–24years compared to those aged ≥25years. Differences between populations persisted after adjusting for sex, age and data source. In general, compared to our previous analysis, the proportion of people with an HbA1c<58mmol/l (<7.5%) increased and proportions of people with HbA1c≥ 75mmol/mol (≥9.0%) decreased. Conclusions: Glycaemic control of type 1 diabetes continues to vary substantially between age groups and data sources. While some improvement over time has been observed, glycaemic control remains sub-optimal for most people with Type 1 diabetes.
12.	Band, D. L., et al. (författare) Prospects for GRB Science with the Fermi Large Area Telescope 2009 Ingår i: Astrophysical Journal. - 0004-637X .- 1538-4357. ; 701:2, s. 1673-1694 Tidskriftsartikel (refereegranskat)abstract The Large Area Telescope (LAT) instrument on the Fermi mission will reveal the rich spectral and temporal gamma-ray burst (GRB) phenomena in the >100 MeV band. The synergy with Fermi's Gamma-ray Burst Monitor detectors will link these observations to those in the well explored 10-1000 keV range; the addition of the >100 MeV band observations will resolve theoretical uncertainties about burst emission in both the prompt and afterglow phases. Trigger algorithms will be applied to the LAT data both onboard the spacecraft and on the ground. The sensitivity of these triggers will differ because of the available computing resources onboard and on the ground. Here we present the LAT's burst detection methodologies and the instrument's GRB capabilities.
13.	Bastard, P, et al. (författare) Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1 2021 Ingår i: The Journal of experimental medicine. - : Rockefeller University Press. - 1540-9538 .- 0022-1007. ; 218:7 Tidskriftsartikel (refereegranskat)abstract Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.
14.	Danne, T., et al. (författare) Insulin treatment in children and adolescents with diabetes 2014 Ingår i: Pediatric Diabetes. - : Blackwell Publishing Ltd. - 1399-543X .- 1399-5448. ; 15:SUPPL.20, s. 115-134 Tidskriftsartikel (refereegranskat)
15.	Danne, T., et al. (författare) ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes 2018 Ingår i: Pediatric Diabetes. - : Hindawi Limited. - 1399-543X. ; 19:527, s. 115-135 Tidskriftsartikel (refereegranskat)
16.	Schnell, O, et al. (författare) CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes 2023 Ingår i: Cardiovascular diabetology. - : Springer Science and Business Media LLC. - 1475-2840. ; 22:1, s. 59- Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (http://www.cvot.org).
17.	Schnell, O, et al. (författare) Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes 2022 Ingår i: Cardiovascular diabetology. - : Springer Science and Business Media LLC. - 1475-2840. ; 21:1, s. 50- Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year’s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1–5, and STEP 1–5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registrationThe 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10–11, 2022 (http://www.cvot.org)
18.	Boehm, M, et al. (författare) Kidney Transplantation in Small Children: Association Between Body Weight and Outcome-A Report From the ESPN/ERA-EDTA Registry 2022 Ingår i: Transplantation. - 1534-6080. ; 106:3, s. 607-614 Tidskriftsartikel (refereegranskat)
19.	Boehm, M, et al. (författare) Kidney Transplantation in Small Children: Association Between Body Weight and Outcome-A Report From the ESPN/ERA-EDTA Registry 2022 Ingår i: Transplantation. - 1534-6080. ; 106:3, s. 607-614 Tidskriftsartikel (refereegranskat)
20.	Garg, S, et al. (författare) Self-monitoring of blood glucose 2010 Ingår i: International journal of clinical practice. Supplement. - : Hindawi Limited. - 1368-504X .- 1368-5031 .- 1742-1241. ; 64:166, s. 1-69 Tidskriftsartikel (refereegranskat)
21.	Gavin, JR, et al. (författare) Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases - Recommendations from the taskforce of the guideline workshop 2024 Ingår i: Diabetes research and clinical practice. - 1872-8227. ; 211, s. 111666- Tidskriftsartikel (refereegranskat)
22.	Gerhardsson, P., et al. (författare) The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes 2021 Ingår i: Diabetes Technology & Therapeutics. - : Mary Ann Liebert Inc. - 1520-9156 .- 1557-8593. ; 23:7 Tidskriftsartikel (refereegranskat)abstract Objective: The international SWEET registry (NCT04427189) was initiated in 2008 to improve outcomes in pediatric diabetes. A 10-year follow-up allowed studying time trends of key quality indicators in 22 centers from Europe, Australia, Canada, and India in youth with type 1 diabetes (T1D). Methods: Aggregated data per person with T1D <25 years of age were compared between 2008-2010 and 2016-2018. Hierarchic linear and logistic regression models were applied. Models were adjusted for gender, age-, and diabetes duration groups. Results: The first and second time periods included 4930 versus 13,654 persons, 51% versus 52% male, median age 11.3 [Q1; Q3: 7.9; 14.5] versus 13.3 [9.7; 16.4] years, and T1D duration 2.9 [0.8; 6.4] versus 4.2 [1.4; 7.7] years. The adjusted hemoglobin A1C (HbA1c) improved from 68 (95% confidence interval [CI]: 66-70) to 63 (60; 65) mmol/mol (P<0.0001) or 8.4 (95% CI: 8.2-8.6) to 7.9 (7.6; 8.1) % (P<0.0001). Across all age groups, HbA1c was significantly lower in pump and sensor users. Severe hypoglycemia declined from 3.8% (2.9; 5.0) to 2.4% (1.9; 3.1) (P<0.0001), whereas diabetic ketoacidosis events increased significantly with injection therapy only. Body mass index-standard deviation score also showed significant improvements 0.55 (0.46; 0.64) versus 0.42 (0.33; 0.51) (P<0.0001). Over time, the increase in pump use from 34% to 44% preceded the increase in HbA1c target achievement (<53mmol/mol) from 21% to 34%. Conclusions: Twice yearly benchmarking within the SWEET registry was associated with significantly improved HbA1c on a background of increasing pump and sensor use for 10 years in young persons with T1D.
23.	Moser, O., et al. (författare) Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA) 2020 Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 63, s. 2501-2520 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract Physical exercise is an important component in the management of type 1 diabetes across the lifespan. Yet, acute exercise increases the risk of dysglycaemia, and the direction of glycaemic excursions depends, to some extent, on the intensity and duration of the type of exercise. Understandably, fear of hypoglycaemia is one of the strongest barriers to incorporating exercise into daily life. Risk of hypoglycaemia during and after exercise can be lowered when insulin-dose adjustments are made and/or additional carbohydrates are consumed. Glycaemic management during exercise has been made easier with continuous glucose monitoring (CGM) and intermittently scanned continuous glucose monitoring (isCGM) systems; however, because of the complexity of CGM and isCGM systems, both individuals with type 1 diabetes and their healthcare professionals may struggle with the interpretation of given information to maximise the technological potential for effective use around exercise (i.e. before, during and after). This position statement highlights the recent advancements in CGM and isCGM technology, with a focus on the evidence base for their efficacy to sense glucose around exercise and adaptations in the use of these emerging tools, and updates the guidance for exercise in adults, children and adolescents with type 1 diabetes.
24.	Pham, M N., et al. (författare) Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes 2013 Ingår i: Diabetologia. - : Springer Verlag (Germany). - 0012-186X .- 1432-0428. ; 56:6, s. 1356-1363 Tidskriftsartikel (refereegranskat)abstract Cytokines may promote or inhibit disease progression in type 1 diabetes. We investigated whether systemic proinflammatory, anti-inflammatory and regulatory cytokines associated differently with fasting and meal-stimulated beta cell function in patients with longer term type 1 diabetes. less thanbrgreater than less thanbrgreater thanThe beta cell function of 118 patients with type 1 diabetes of duration of 0.75-4.97 years was tested using a standardised liquid mixed meal test (MMT). Serum samples obtained at -5 to 120 min were analysed by multiplex bead-based technology for proinflammatory (IL-6, TNF-alpha), anti-inflammatory (IL-1 receptor antagonist [IL-1RA]) and regulatory (IL-10, TGF-beta(1-3)) cytokines, and by standard procedures for C-peptide. Differences in beta cell function between patient groups were assessed using stepwise multiple regression analysis adjusting for sex, age, duration of diabetes, BMI, HbA(1c) and fasting blood glucose. less thanbrgreater than less thanbrgreater thanHigh fasting systemic concentrations of the proinflammatory cytokines IL-6 and TNF-alpha were associated with increased fasting and stimulated C-peptide concentrations even after adjustment for confounders (p andlt; 0.03). Interestingly, increased concentrations of anti-inflammatory/regulatory IL-1RA, IL-10, TGF-beta(1) and TGF-beta(2) were associated with lower fasting and stimulated C-peptide levels (p andlt; 0.04), losing significance on adjustment for anthropometric variables. During the MMT, circulating concentrations of IL-6 and TNF-alpha increased (p andlt; 0.001) while those of IL-10 and TGF-beta(1) decreased (p andlt; 0.02) and IL-1RA and TGF-beta(2) remained unchanged. less thanbrgreater than less thanbrgreater thanThe association between better preserved beta cell function in longer term type 1 diabetes and increased systemic proinflammatory cytokines and decreased anti-inflammatory and regulatory cytokines is suggestive of ongoing inflammatory disease activity that might be perpetuated by the remaining beta cells. These findings should be considered when designing immune intervention studies aimed at patients with longer term type 1 diabetes and residual beta cell function.
25.	Battelino, T, et al. (författare) Guideline Development for Medical Device Technology: Issues for Consideration 2023 Ingår i: Journal of diabetes science and technology. - : SAGE Publications. - 1932-2968. ; 17:6, s. 1698-1710 Tidskriftsartikel (refereegranskat)abstract Advances in the development of innovative medical devices and telehealth technologies create the potential to improve the quality and efficiency of diabetes care through collecting, aggregating, and interpreting relevant health data in ways that facilitate more informed decisions among all stakeholder groups. Although many medical societies publish guidelines for utilizing these technologies in clinical practice, we believe that the methodologies used for the selection and grading of the evidence should be revised. In this article, we discuss the strengths and limitations of the various types of research commonly used for evidence selection and grading and present recommendations for modifying the process to more effectively address the rapid pace of device and technology innovation and new product development.
26.	Battelino, T, et al. (författare) Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial 2017 Ingår i: Clinical endocrinology. - : Wiley. - 1365-2265 .- 0300-0664. ; 87:4, s. 350-358 Tidskriftsartikel (refereegranskat)
27.	Battelino, T, et al. (författare) The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial 2012 Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 1432-0428 .- 0012-186X. ; 55:12, s. 3155-3162 Tidskriftsartikel (refereegranskat)
28.	Biver, N., et al. (författare) Isotopic ratios of H, C, N, O, and S in comets C/2012 F6 (Lemmon) and C/2014 Q2 (Lovejoy) 2016 Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 589, s. Art. no. A78- Tidskriftsartikel (refereegranskat)abstract The apparition of bright comets C/2012 F6 (Lemmon) and C/2014 Q2 (Lovejoy) in March-April 2013 and January 2015, combined with the improved observational capabilities of submillimeter facilities, offered an opportunity to carry out sensitive compositional and isotopic studies of the volatiles in their coma. We observed comet Lovejoy with the IRAM 30 m telescope between 13 and 26 January 2015, and with the Odin submillimeter space observatory on 29 January-3 February 2015. We detected 22 molecules and several isotopologues. The (H2O)-O-16 and (H2O)-O-18 production rates measured with Odin follow a periodic pattern with a period of 0.94 days and an amplitude of similar to 25%. The inferred isotope ratios in comet Lovejoy are O-16/O-18 = 499 +/- 24 and D/H = 1.4 +/- 0.4 x 10(-4) in water, S-32/S-34 = 24.7 +/- 3.5 in CS, all compatible with terrestrial values. The ratio C-12/C-13 = 109 +/- 14 in HCN is marginally higher than terrestrial and N-14/N-15 = 145 +/- 12 in HCN is half the Earth ratio. Several upper limits for D/H or C-12/C-13 in other molecules are reported. From our observation of HDO in comet C/2014 Q2 (Lovejoy), we report the first D/H ratio in an Oort Cloud comet that is not larger than the terrestrial value. On the other hand, the observation of the same HDO line in the other Oort-cloud comet, C/2012 F6 (Lemmon), suggests a D/H value four times higher. Given the previous measurements of D/H in cometary water, this illustrates that a diversity in the D/H ratio and in the chemical composition, is present even within the same dynamical group of comets, suggesting that current dynamical groups contain comets formed at very different places or times in the early solar system.
29.	Bolinder, J, et al. (författare) Guardian (R) RT Continuous Glucose Monitoring System with real time glucose values and alarms functions: a new tool for improving glucose control in patients with type 1 diabetes mellitus? 2005 Ingår i: DIABETOLOGIA. - 0012-186X. ; 48, s. A49-A49 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
30.	Brandt, S, et al. (författare) Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children 2018 Ingår i: Pediatric obesity. - : Wiley. - 2047-6310 .- 2047-6302. ; 13:3, s. 175-182 Tidskriftsartikel (refereegranskat)
31.	Ceriello, A, et al. (författare) Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop 2023 Ingår i: Cardiovascular diabetology. - 1475-2840. ; 22:1, s. 277- Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
32.	Cianfarani, S, et al. (författare) A Critical Review of Upcoming New Therapeutic Options in Paediatric Endocrinology 2024 Ingår i: Hormone research in paediatrics. - 1663-2826. ; 97:3, s. 215-217 Forskningsöversikt (övrigt vetenskapligt/konstnärligt)
33.	Conget, I, et al. (författare) The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy 2011 Ingår i: Diabetes technology & therapeutics. - : Mary Ann Liebert Inc. - 1557-8593 .- 1520-9156. ; 13:1, s. 49-54 Tidskriftsartikel (refereegranskat)
34.	Danne, Thomas, et al. (författare) Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes : Experience of the PedPump Study in 17 countries 2008 Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 51:9, s. 1594-1601 Tidskriftsartikel (refereegranskat)abstract Aims/hypothesis: To assess the use of paediatric continuous subcutaneous infusion (CSII) under real-life conditions by analysing data recorded for up to 90 days and relating them to outcome. Methods: Pump programming data from patients aged 0-18 years treated with CSII in 30 centres from 16 European countries and Israel were recorded during routine clinical visits. HbA 1c was measured centrally. Results: A total of 1,041 patients (age: 11.8±4.2 years, diabetes duration: 6.0±3.6 years, average CSII duration: 2.0±1.3 years, HbA1c: 8.0±1.3% [means±SD]) participated. Glycaemic control was better in preschool (n=142, 7.5±0.9%) and pre-adolescent (6-11 years, n=321, 7.7±1.0%) children than in adolescent patients (12-18 years, n=578, 8.3±1.4%). There was a significant negative correlation between HbA1c and daily bolus number, but not between HbA1c and total daily insulin dose. The use of <6.7 daily boluses was a significant predictor of an HbA1c level >7.5%. The incidence of severe hypoglycaemia and ketoacidosis was 6.63 and 6.26 events per 100 patient-years, respectively. Conclusions/ interpretation: This large paediatric survey of CSII shows that glycaemic targets can be frequently achieved, particularly in young children, and the incidence of acute complications is low. Adequate substitution of basal and prandial insulin is associated with a better HbA1c. © 2008 Springer-Verlag.
35.	Deis, D, et al. (författare) Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring 2006 Ingår i: Diabetes care. - : American Diabetes Association. - 0149-5992 .- 1935-5548. ; 29:12, s. 2730-2732 Tidskriftsartikel (refereegranskat)
36.	Fischer-Posovszky, P, et al. (författare) Functional Significance and Predictive Value of MicroRNAs in Pediatric Obesity: Tiny Molecules with Huge Impact? 2016 Ingår i: Hormone research in paediatrics. - : S. Karger AG. - 1663-2826 .- 1663-2818. ; 86:1, s. 3-10 Tidskriftsartikel (refereegranskat)abstract Obesity is a major health concern. While some children develop comorbidities such as insulin resistance and low-grade systemic inflammation upon weight gain, others stay metabolically healthy. There is an urgent need for clinically relevant markers with prognostic value related to disease development and intervention success. MicroRNAs (miRNAs) are established biomarkers for several disease states. Herein, we give a brief overview of miRNA biogenesis and function and the potential role of circulating miRNA in the context of pediatric obesity.
37.	Harambat, J, et al. (författare) Adult height in patients with advanced CKD requiring renal replacement therapy during childhood 2014 Ingår i: Clinical journal of the American Society of Nephrology : CJASN. - 1555-905X. ; 9:1, s. 92-99 Tidskriftsartikel (refereegranskat)
38.	Hommel, E, et al. (författare) Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study 2014 Ingår i: Acta diabetologica. - : Springer Science and Business Media LLC. - 1432-5233 .- 0940-5429. ; 51:5, s. 845-851 Tidskriftsartikel (refereegranskat)
39.	Mandrup-Poulsen, TR, et al. (författare) The European C-Peptide Trial CPT: comparison of liquid mixed meal and glucagon stimulation assays for the analysis of residual beta cell function in type 1 diabetes 2006 Ingår i: DIABETOLOGIA. - 0012-186X. ; 49, s. 375-376 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
40.	Mlinaric, M, et al. (författare) Newborn Screening in a Pandemic-Lessons Learned 2023 Ingår i: International journal of neonatal screening. - 2409-515X. ; 9:2 Tidskriftsartikel (refereegranskat)
41.	Nowotny, HF, et al. (författare) Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21-hydroxylase deficiency in Europe 2021 Ingår i: HORMONE RESEARCH IN PAEDIATRICS. - 1663-2818. ; 94:SUPPL 1, s. 145-146 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
42.	Nowotny, H, et al. (författare) Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe 2022 Ingår i: European journal of endocrinology. - 1479-683X. ; 186:5, s. K17-K24 Tidskriftsartikel (refereegranskat)
43.	Riveline, JP, et al. (författare) Improvement of the glycemic equilibrium in patients with diabetes type 1 using system of the continued evaluation of the glucose by reading the results in real-time: results of the Guardcontrol study 2006 Ingår i: DIABETES & METABOLISM. - 1262-3636. ; 32, s. S15-S15 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
44.	Savendahl, L, et al. (författare) Corrigendum to: "Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial" 2020 Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 1945-7197 .- 0021-972X. ; 105:12 Tidskriftsartikel (refereegranskat)
45.	Savendahl, L, et al. (författare) Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial 2022 Ingår i: HORMONE RESEARCH IN PAEDIATRICS. - 1663-2818. ; 95:SUPPL 2, s. 85-85 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
46.	Savendahl, L, et al. (författare) Letter to the Editor From Sävendahl et al.: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial" 2022 Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 1945-7197 .- 0021-972X. ; 107:2, s. E888-E889 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
47.	Savendahl, L, et al. (författare) Once-weekly somapacitan versus daily growth hormone in growth hormone deficiency: 3-year efficacy and safety results from REAL 3, a randomised controlled phase 2 trial 2021 Ingår i: HORMONE RESEARCH IN PAEDIATRICS. - 1663-2818. ; 94:SUPPL 1, s. 57-58 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
48.	Savendahl, L, et al. (författare) Once-weekly somapacitan vs daily growth hormone (Norditropin (R)) in childhood growth hormone deficiency: One-year results from a randomised phase 2 trial 2019 Ingår i: HORMONE RESEARCH IN PAEDIATRICS. - 1663-2818. ; 91, s. 64-65 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
49.	Savendal, L, et al. (författare) Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial 2018 Ingår i: HORMONE RESEARCH IN PAEDIATRICS. - 1663-2818. ; 90, s. 58-58 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
50.	Sikonja, J, et al. (författare) Towards Achieving Equity and Innovation in Newborn Screening across Europe 2022 Ingår i: International journal of neonatal screening. - : MDPI AG. - 2409-515X. ; 8:2 Tidskriftsartikel (refereegranskat)abstract Although individual rare disorders are uncommon, it is estimated that, together, 6000+ known rare diseases affect more than 30 million people in Europe, and present a substantial public health burden. Together with the psychosocial burden on affected families, rare disorders frequently, if untreated, result in a low quality of life, disability and even premature death. Newborn screening (NBS) has the potential to detect a number of rare conditions in asymptomatic children, providing the possibility of early treatment and a significantly improved long-term outcome. Despite these clear benefits, the availability and conduct of NBS programmes varies considerably across Europe and, with the increasing potential of genomic testing, it is likely that these differences may become even more pronounced. To help improve the equity of provision of NBS and ensure that all children can be offered high-quality screening regardless of race, nationality and socio-economic status, a technical meeting, endorsed by the Slovenian Presidency of the Council of the European Union, was held in October 2021. In this article, we present experiences from individual EU countries, stakeholder initiatives and the meeting’s final conclusions, which can help countries attempting to establish new NBS programmes or expand existing provision.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Träfflista för sökning "WFRF:(Battelino T) "

Avgränsa träffmängd

År